Oct 1, 2020Paper

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

BioRxiv : the Preprint Server for Biology
Alexandra SchäferTimothy P Sheahan


SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million infections and 800,000 deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a mouse adapted model of SARS-CoV-2 infection (SARS-CoV-2 MA). In vitro antibody neutralization potency did not uniformly correlate with in vivo activity, and some hu-mAbs were more potent in combination in vivo . Analysis of antibody Fc regions revealed that binding to activating Fc receptors is essential for optimal protection against SARS-CoV-2 MA. The data indicate that hu-mAb protective activity is dependent on intact effector function and that in vivo testing is required to establish optimal hu-mAb combinations for COVID-19 prevention.


Jan 5, 2021·Frontiers in Immunology·Yannick GalipeauMarc-André Langlois
Jan 7, 2021·Military Medical Research·Dan-Dan Li, Qi-Han Li
Mar 23, 2021·Expert Opinion on Therapeutic Targets·Simone I Richardson, Penny L Moore
Apr 4, 2021·Microorganisms·Alessio Danilo InchingoloGianna Dipalma
Jun 3, 2021·Antioxidants·Alessio Danilo InchingoloFrancesco Inchingolo

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.